Dagapamil

A fictional calcium channel blocker

{{Drugbox | Verifiedfields = changed | verifiedrevid = 123456789 | IUPAC_name = (2S)-2-[[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]propyl]methylamino]-3-phenylpropanoic acid | image = | width = 200 | tradename = Dagapamil | Drugs.com = | MedlinePlus = | pregnancy_AU = | pregnancy_US = | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration = Oral | bioavailability = 20% | protein_bound = 90% | metabolism = Hepatic | elimination_half-life = 4-6 hours | excretion = Renal }}

Dagapamil is a calcium channel blocker that is primarily used in the management of hypertension and angina pectoris. It belongs to the class of phenylalkylamine calcium channel blockers, similar to verapamil.

Mechanism of Action

Dagapamil works by inhibiting the influx of calcium ions through L-type calcium channels in the cardiac muscle and vascular smooth muscle. This action results in a decrease in myocardial contractility and a reduction in peripheral vascular resistance, leading to a decrease in blood pressure and relief from angina.

Pharmacokinetics

Dagapamil is administered orally and has a bioavailability of approximately 20% due to extensive first-pass metabolism in the liver. It is highly protein-bound (90%) and is metabolized primarily by the liver. The elimination half-life of dagapamil is between 4 to 6 hours, and it is excreted mainly through the kidneys.

Clinical Uses

Dagapamil is indicated for the treatment of:

• Hypertension
• Angina pectoris

Side Effects

Common side effects of dagapamil include:

• Dizziness
• Headache
• Constipation
• Bradycardia

Contraindications

Dagapamil is contraindicated in patients with:

• Severe hypotension
• Cardiogenic shock
• Second- or third-degree atrioventricular block (unless a functioning pacemaker is present)

Drug Interactions

Dagapamil may interact with other medications, including:

• Beta-blockers: May increase the risk of bradycardia and hypotension.
• Digoxin: May increase digoxin levels, leading to toxicity.
• CYP3A4 inhibitors: May increase the plasma concentration of dagapamil.

Also see

• Calcium channel blocker
• Verapamil
• Hypertension
• Angina pectoris